

Special Article - Colorectal Cancer

Colorectal Cancer: Up To Date Oncolytic Virotherapy

Yigang Wang*

Xinyuan Institute of Medicine and Biotechnology, School of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, 310014, China

***Corresponding author:** Yigang Wang, Xinyuan Institute of Medicine and Biotechnology, School of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, 310014, China

Received: July 19, 2018; **Accepted:** August 03, 2018;

Published: August 10, 2018

Letter to Editor

Oncolytic virotherapy is one of the most attractive and emerging approach for treating human cancers including colorectal cancer, boosted by the recent approval of talimogene laherparepvec (TVEC) by FDA, a modified herpes simplex virus 1 encoding human GM-

CSF, for use in stage III melanoma patients. Oncolytic viruses (OV) are nonpathogenic viral strains that selectively kill malignant cells upon replication, while sparing normal cells. The current OV used in antitumoral therapies includes adenovirus, poxvirus, herpes simplex virus, new castle disease virus, Measles virus, reovirus, vesicular stomatitis virus etc. Focusing on oncolytic adenovirus, our group has successfully performed several anti-colorectal cancer therapy in preclinical level in past decade year. There are 7 clinical trials for Colorectal Cancer therapy by using oncolytic virus alone or combination therapy with immunotherapy, indicating the promising prospect.